why choose us

First received: March 24, 2023

Clinical Trial: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neovascular Age-related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Brief Summary: The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD.The main question[s] it aims to answer are:Safety of the maximum tolerable dose of AXT107Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.

Read more